钇90树脂微球放射段切除术治疗肝细胞癌的疗效与安全性
这项回顾性单中心研究纳入2014年7月至2022年12月接受钇90树脂微球放射段切除术的67例成人肝细胞癌患者,采用单室MIRD模型确定剂量。治疗后中位肿瘤吸收剂量为232 Gy;3个月时病灶水平和整体完全缓解率分别为70%和61%;1个月时1例(1.5%)发生3级不良事件(腹痛)。肿瘤接受300 Gy及以上者2年疾病进展率低于不足300 Gy者(17% vs 61%;P = .047)。
要点
- 放射段切除术治疗后中位肿瘤吸收剂量为232 Gy,3个月时病灶水平和整体完全缓解率分别为70%和61%。
- 88%和72%的患者分别达到病灶水平和整体缓解持续时间1年及以上。
- 肿瘤吸收剂量300 Gy及以上组2年疾病进展率低于不足300 Gy组(17% vs 61%;P = .047),前者随访期内无局部进展。
核心结论
- 接受钇90树脂微球放射段切除术的肝细胞癌患者中,88%和72%分别达到病灶水平和整体缓解持续时间1年及以上,仅发生1例3级不良事件;治疗后剂量学显示肿瘤接受300 Gy及以上者可见疾病进展获益。
研究设计与样本
- 回顾性单中心研究,纳入2014年7月至2022年12月接受钇90树脂微球放射段切除术的67例成人肝细胞癌患者(中位年龄69岁,IQR 63-78岁;54例男性),采用单室MIRD模型确定剂量,治疗后行PET/CT和剂量学评估。
诊断标准与关键数值
- 采用mRECIST评估病灶水平和整体(按患者)完全缓解、客观缓解、疾病控制及缓解持续时间;不良事件采用常见不良事件评价标准5.0版评估;中位肿瘤吸收剂量232 Gy(IQR 163-405 Gy);3个月时病灶水平和整体完全缓解率分别为70%(47/67)和61%(41/67);6个月时(n=46)病灶水平和整体客观缓解率与疾病控制率均分别为94%和78%;病灶水平和整体缓解持续时间1年及以上的患者比例分别为88%(95% CI:79-99)和72%(95% CI:58-90);1个月时3级临床不良事件(腹痛)发生率为1.5%(1/67);中位治疗后总生存期26个月(95% CI:20-未达到);2年疾病进展率在肿瘤吸收剂量300 Gy及以上组为17%,不足300 Gy组为61%(P = .047)。
临床应用与阅片要点
- 对肝细胞癌行钇90树脂微球放射段切除术时,可依据治疗后PET/CT剂量学评估肿瘤吸收剂量,肿瘤吸收剂量300 Gy及以上与2年疾病进展率更低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Limited data are available on radiation segmentectomy (RS) for treatment of hepatocellular carcinoma (HCC) using yttrium 90 (90Y) resin microsphere doses determined by using a single-compartment medical internal radiation dosimetry (MIRD) model. Purpose To evaluate the efficacy and safety of RS treatment of HCC with 90Y resin microspheres using a single-compartment MIRD model and correlate posttreatment dose with outcomes. Materials and Methods This retrospective single-center study included adult patients with HCC who underwent RS with 90Y resin microspheres between July 2014 and December 2022. Posttreatment PET/CT and dosimetry were performed. Adverse events were assessed using the Common Terminology Criteria for Adverse Events, version 5.0. Per-lesion and overall response rates (ie, complete response [CR], objective response, disease control, and duration of response) were assessed at imaging using the Modified Response Evaluation Criteria in Solid Tumors, and overall survival (OS) was assessed using Kaplan-Meier analysis. Results Among 67 patients (median age, 69 years [IQR, 63-78 years]; 54 male patients) with HCC, median tumor absorbed dose was 232 Gy (IQR, 163-405 Gy). At 3 months, per-lesion and overall (per-patient) CR was achieved in 47 (70%) and 41 (61%) of 67 patients, respectively. At 6 months (n = 46), per-lesion rates of objective response and disease control were both 94%, and per-patient rates were both 78%. A total of 88% (95% CI: 79 99) and 72% (95% CI: 58, 90) of patients had a per-lesion and overall duration of response of 1 year or greater. At 1 month, a grade 3 clinical adverse event (abdominal pain) occurred in one of 67 (1.5%) patients. Median posttreatment OS was 26 months (95% CI: 20, not reached). Disease progression at 2 years was lower in the group that received 300 Gy or more than in the group that received less than 300 Gy (17% vs 61%; P = .047), with no local progression in the former group through the end of follow-up. Conclusion Among patients with HCC who underwent RS with 90Y resin microspheres, 88% and 72% achieved a per-lesion and overall duration of response of 1 year or greater, respectively, with one grade 3 adverse event. In patients whose tumors received 300 Gy or more according to posttreatment dosimetry, a disease progression benefit was noted. © RSNA, 2024 Supplemental material is available for this article.
引用
- Sarwar A, Malik MS, Vo NH, et al. Efficacy and Safety of Radiation Segmentectomy with 90Y Resin Microspheres for Hepatocellular Carcinoma. Radiology. 2024. PMID: 38713023. doi:10.1148/radiol.231386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。